Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Dose escalation

<< Previous

Bullboard Posts

Next >>

Comment by jeffm34on Jul 18, 2021 2:35pm

138 Views

Post# 33567027

RE:RE:RE:Dose escalation

TH1902 doesn't need to be transformative to be successful anyways. Even if it's only as effective as Docetaxel alone but has less risk of side effects like neutropenia, it will still be an attractive drug to use over current therapy.

qwerty22 wrote:
The goal for thtx is to get on the list in the first place with an approval. And second to have as strong a profile as possible so doctors are reaching for that drug as often as possible and eventually as early as possible. I think cancer analysts are looking to fit the drug in the pre-existing treatment landscape in a practical way, they aren't looking for transformative statements.